

To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 13.02.2025

Unit: Decipher Labs Limited (Scrip Code: 524752)

Sub: Outcome of Board Meeting for the quarter and nine months ended 31.12.2024 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Thursday, the 13th day of February, 2025 at 05.00 P.M. at registered office of the Company, inter alia approved the following items of business:

1. Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine months ended 31st December, 2024. (Enclosed as **Annexure I**).
2. Limited Review Report (Standalone and Consolidated) for the Quarter and Nine months ended 31st December, 2024. (Enclosed as **Annexure II**).

The meeting concluded at 06:50 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Faithfully

For Decipher Labs Limited

Sushant Mohan Lal
Executive Director
(DIN- 01227151)
Encl. as above

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)

Regd. off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Unaudited Standalone Financial Results For the Quarter and Nine Months Ended 31st December, 2024

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine Months Ended		Year ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	16.00	8.38	17.49	62.72	17.49	353.16
II. Other income	0.33	1.77	0.49	2.27	1.49	1.99
III. Total Income (I + II)	16.33	10.15	17.98	64.99	18.98	355.14
IV. Expenses						
Purchase of Stock in trade	15.00	-	-	44.25	-	313.77
Changes in inventories of stock in trade	-	-	-	-	-	-
Employee Benefits Expense	3.01	4.40	4.24	15.13	12.74	16.99
Finance Costs	-	-	-	-	-	-
Depreciation expense	0.45	0.45	0.37	1.22	1.10	1.45
Other expenses	6.96	11.05	4.05	31.84	15.38	20.42
Total expenses	25.43	15.90	8.66	92.45	29.22	352.63
V. Profit/(Loss) before Exceptional items (III - IV)	(9.09)	(5.75)	9.33	(27.45)	(10.23)	2.51
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) after Exceptional items (V - VI)	(9.09)	(5.75)	9.33	(27.45)	(10.23)	2.51
VIII. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(0.12)	(0.11)	0.03	0.24	0.16	(0.18)
IX. Profit/(Loss) for the period (VII-VIII)	(8.97)	(5.64)	9.30	(27.69)	(10.39)	2.33
X. Other comprehensive income	-	-	-	-	-	-
XI. Total comprehensive income for the year	(8.97)	(5.64)	9.30	(27.69)	(10.39)	2.33
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XII. Earning per equity share						
(1) Basic	(0.09)	(0.06)	0.09	(0.27)	(0.10)	0.02
(2) Diluted	(0.09)	(0.06)	0.09	(0.27)	(0.10)	0.02

Notes

1. The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Nine Months Ended		Year Ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	16.00	-	-	46.00	-	327.33
b) Consultancy Services	0.00	8.34	17.49	16.72	17.49	25.83
Total Sales	16.00	8.34	17.49	62.72	17.49	353.16
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	16.00	8.34	17.49	62.72	17.49	353.16
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(8.34)	(1.92)	-	(20.13)	(19.56)	2.33
b) Consultancy Services	(0.75)	(3.83)	9.33	(7.32)	9.33	0.18
Total	(9.09)	(5.75)	9.33	(27.45)	(10.23)	2.52
Less: Interest and exceptional items	-	-	-	-	-	-
Total Profit before tax	(9.09)	(5.75)	9.33	(27.45)	(10.23)	2.52
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	910.76	893.52	883.73	910.76	883.73	1,267.85
b) Consultancy Services	17.12	16.73	9.07	17.12	9.07	8.25
Total Assets	927.88	910.25	892.80	927.88	892.80	1,276.10
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	62.81	20.30	12.82	62.81	12.82	383.34
b) Consultancy Services	-	-	-	-	-	-
c) Unallocated liabilities	-	-	-	-	-	-
Total Liabilities	62.81	20.30	12.82	62.81	12.82	383.34

2. The above results for the period ended 31st December 2024 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th February 2025.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Place: Hyderabad
Date: 13.02.2025



For and on behalf of the Board

Sushant Mohan Lal
Sushant Mohan Lal
Executive Director
DIN: 01227151

DECIPHER LABS LIMITED. (CIN CL23230TG1986PLC006781)

Regd.off: A-2, Q2, 5th Floor, Cyber Towers, Madhapur, Hyderabad, Telangana, India - 500081
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-29323151

Statement of Unaudited Consolidated Financial Results For the Quarter and Nine Months Ended December 31, 2024

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	580.47	586.67	828.62	1,911.24	2,528.73	3,587.85
II. Other income	16.87	12.09	0.26	44.77	14.55	41.65
III.Total revenue (I + II)	597.34	598.76	828.88	1,956.01	2,543.28	3,629.51
IV. Expenses						
Purchase of Stock-in-Trade	15.00	-	-	44.25	-	313.77
Changes in inventories of finished goods and stock in trade	-	-	-	-	-	-
Employee benefits expense	582.82	668.72	651.97	1,762.89	2,234.72	2,774.94
Finance costs	-	-	-	-	0.52	21.76
Depreciation and amortisation expense	12.20	11.50	11.69	34.98	34.12	45.27
Other expenses	45.79	51.28	163.80	169.31	511.30	594.88
Total expenses	655.81	731.50	827.46	2,011.43	2,780.66	3,750.62
V. Profit/(Loss) before Exceptional item (III - IV)	(58.47)	(132.73)	1.42	(55.42)	(237.38)	(121.11)
VI.Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) before tax (III - IV)	(58.47)	(132.73)	1.42	(55.42)	(237.38)	(121.11)
VIII. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	0.80	0.06	0.38	41.99	50.67	46.45
IX. Profit/(Loss) for the period (V-VI)	(59.27)	(132.80)	1.04	(97.41)	(288.05)	(167.56)
X. Other comprehensive income						
Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	22.12	28.26	13.87	50.14	28.02	32.77
XI. Total comprehensive income for the year	(37.16)	(104.54)	14.91	(47.28)	(260.03)	(134.79)
Net Profit/(Loss) for the year attributable to:						
Owners of the parent	(59.27)	(132.80)	1.04	(97.41)	(288.05)	(167.56)
Non-Controlling Interests	-	-	-	-	-	-
Other Comprehensive Income attributable to:						
Owners of the parent	(37.16)	(104.54)	14.91	(47.28)	(260.03)	(134.79)
Non-Controlling Interests	-	-	-	-	-	-
Total Comprehensive Income attributable to:						
Owners of the parent	(37.16)	(104.54)	14.91	(47.28)	(260.03)	(134.79)
Non-Controlling Interests	-	-	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00	1,010.00
XI. Earning per equity share						
(1) Basic	(0.59)	(1.31)	0.01	(0.96)	(2.85)	(1.66)
(2) Diluted	(0.59)	(1.31)	0.01	(0.96)	(2.85)	(1.66)

Notes

1. The operations of the Group relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	16.00	-	-	46.00	-	327.33
b) Consultancy Services	564.47	586.67	828.63	1,865.24	2,528.74	3,260.53
Total Sales	580.47	586.67	828.63	1,911.24	2,528.74	3,587.86
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	580.47	586.67	828.63	1,911.24	2,528.74	3,587.86
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	(8.34)	(17.34)	9.33	(20.13)	(10.23)	(9.06)
b) Consultancy Services	(50.21)	(115.40)	(7.91)	(35.29)	(226.62)	(90.29)
Total	(58.55)	(132.74)	1.42	(55.42)	(236.85)	(99.35)
Less: Interest and exceptional item	-	-	-	-	0.52	21.76
Total Profit/(Loss) before tax	(58.55)	(132.74)	1.42	(55.42)	(237.37)	(121.11)

Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	910.76	55.40	45.89	910.76	45.89	427.85
b) Consultancy Services	2,172.16	3,001.36	2,697.74	2,172.16	2,697.74	2,935.46
Total Assets	3,082.92	3,056.75	2,743.63	3,082.92	2,743.63	3,363.31
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	62.81	21.43	15.02	62.81	15.02	383.34
b) Consultancy Services	881.32	882.72	666.51	881.32	666.51	793.91
Total Liabilities	944.13	904.15	681.53	944.13	681.53	1,177.25

2. The above results for the quarter and nine months ended 31 December 2024 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th February 2024.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The above results as of 31 December 2024 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

For and on behalf of the Board



Sushant Mohan Lal
Executive Director
DIN: 01227151



Place: Hyderabad

Date: 13.02.2025




Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher Labs Limited (Formerly known as Combat Drugs Limited) (the "Company") for the quarter ended 31st December, 2024 and year to date results for the period 1st April, 2024 to 31st December, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)


K. Steenivasan

Partner
Membership No.206421

UDIN: 25206421BMIWDD3318

Place : Secunderabad
Date : 13.02.2025





**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

Review Report to The Board of Directors
Decipher Labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 31st December, 2024 and year to date results for the period 1st April, 2024 to 31st December, 2024 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable
4. The Statement includes the results of the subsidiaries Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain.




Ramanatham & Rao

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total revenues of Rs.564.47 lakhs and Rs. 1848.52 lakhs, total net profit (Loss) after tax of Rs. (50.30) lakhs and Rs.(69.72) lakhs, total comprehensive Income of Rs. (28.19) lakhs and Rs. (19.59) lakhs for the quarter ended 31st December, 2024 and for the period from 1st April, 2024 to 31st December, 2024 respectively as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of these subsidiaries is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)



K.Sreenivasan

Partner

Membership No.206421

UDIN: 25206421BMIWDE6655

Place : Secunderabad

Date : 13.02.2025

